Company / Depreciation & Amortization
NeoGenomics Laboratories, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$36.1M
FY2025
5-year range
$30.2M / $39.1M
FY2021-FY2025
Trend
-7.7%
vs FY2024
Sector context
#90 of 141
Health Care
What the data says
At $36M, NeoGenomics Laboratories, Inc.'s depreciation & amortization ranks #52 of 141 in the Health Care sector. Improved from $37M to $36M over the past 2 years.
Based on SEC 10-K filings.
$36M in FY2025 with a 5-year CAGR of +6.8%.
Improved from $37M to $36M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +0.7%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Sector benchmark
#52 of 141 in Health CareTop 36% of 141This company $36.1M Sector average $344.6M
▼
-89.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 7.7% year-over-year.
- Ranks #90 out of 141 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $36.1M | -7.7% |
| FY2024 | $39.1M | +4.4% |
| FY2023 | $37.5M | +5.9% |
| FY2022 | $35.4M | +17.2% |
| FY2021 | $30.2M | +16.6% |
| FY2020 | $25.9M | +27.3% |
| FY2019 | $20.3M | +28.7% |
| FY2018 | $15.8M | +1.3% |
| FY2017 | $15.6M | -2.1% |
| FY2016 | $15.9M | +136.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026